Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897254 | 0.91 | HPGD (0.41) | USP2SMN1; SMN2SCD5NR1H2HPGD | |
| SCHEMBL15368820 | 0.90 | USP2 (0.49) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL30275105 | 0.87 | USP2 (0.43) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL29719128 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2SCD5CYP4F2CYP4A11 | |
| SCHEMBL21603234 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2SCD5CYP4F2CYP4A11 | |
| SCHEMBL17177216 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2SCD5CYP4F2CYP4A11 | |
| SCHEMBL19637316 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2SCD5CYP4F2CYP4A11 | |
| SCHEMBL320729 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2SCD5CYP4F2CYP4A11 | |
| SCHEMBL18129964 | 0.85 | SCD5 (0.41) | USP2SMN1; SMN2SCD5CYP4F2CYP4A11 | |
| SCHEMBL2274901 | 0.85 | USP2 (0.41) | USP2SMN1; SMN2SCD5CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122152-A1 | KAT6 Inhibitors | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-17 | — | — | US | disclosed |
| WO-2025068943-A1 | KAT6 INHIBITORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-03 | — | — | WO | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | USP2 1631/4885SMN1; SMN2 4777/4885SCD5 3611/4885 |
| US-20250122152-A1 | KAT6 Inhibitors | KAT6A, KAT6B, KAT7 | USP2 375/4885SMN1; SMN2 1499/4885SCD5 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.